[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 4341 Introduced in Senate (IS)]

<DOC>






117th CONGRESS
  2d Session
                                S. 4341

 To require the Government Accountability Office to issue a report on 
                nonprofit pharmaceutical organizations.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                              May 26, 2022

 Ms. Rosen (for herself and Mr. Romney) introduced the following bill; 
     which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
 To require the Government Accountability Office to issue a report on 
                nonprofit pharmaceutical organizations.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Advancing Affordable Medicines for 
Families Act''.

SEC. 2. GAO REPORT ON NONPROFIT PHARMACEUTICAL ORGANIZATIONS.

    The Comptroller General of the United States shall submit a report 
to Congress on the following:
            (1) The potential impact of nonprofit pharmaceutical 
        organizations on the availability and cost of drugs, including 
        on drug shortages, consumer costs, and costs to Federal 
        programs.
            (2) The potential of nonprofit pharmaceutical organizations 
        to accelerate development of new drugs, generic drugs, new 
        biological products, biosimilar biological products, cell-based 
        therapies, and devices.
            (3) Existing barriers to the success of nonprofit 
        pharmaceutical organizations, including the ability of such 
        organizations to obtain tax-exempt status, access to capital, 
        and access to markets.
            (4) Potential actions by Congress that would allow 
        nonprofit pharmaceutical organizations to deliver benefits to 
        the pharmaceutical market.
                                 <all>